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As a traditional prognostic factor of breast cancer, axillary
lymph node status has its limitations and much improvement
can still be made in this area. Approximately 40% of women
with positive axillary lymph nodes survive 10 years and, in
contrast, 25–30% of patients with negative axillary lymph
nodes develop relapse.1,2 This problem also exists in patients
with melanoma. Disadvantages of regional lymph node dis-
section include limited survival benefits for node-positive
patients and significant morbidity for node-negative patients,
who are unlikely to obtain therapeutic benefit from this surgi-
cal procedure.3
The “sentinel node”, a term first proposed by Cabanas in
1977, has been accepted as the first node of a regional lym-
phatic basin that receives lymphatic drainage from a specific
tumour site in the modern view of lymphatic mapping.4 Breast
cancer and melanoma are the most commonly studied solid
neoplasms in the application of sentinel lymph node biopsy
(SLNB) due to the high tumour incidence and the accessible
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tumour site for preoperative tracer injection. SLNB is emerg-
ing as an alternative to axillary dissection in the staging of
patients with breast cancer because it is a reliable predictor
of axillary lymph node status.5–9 Furthermore, this more ac-
curate staging is able to identify patients with a very small
tumour burden (lymph node micrometastasis) who might be
eligible for adjuvant treatment.10,11
Much work has been conducted trying to establish micro-
metastasis as a prognostic factor; however, the role of micro-
metastasis and its impact on decision making with respect
to axillary dissection and adjuvant systemic therapy is still
uncertain. Thus, this review will emphasize the possibility of
SLNB or detection of bone marrow micrometastasis replac-
ing traditional axillary lymph node dissection.
Definition of micrometastasis
So far, there is no clear definition of micrometastasis. It has
been proposed that micrometastasis be defined as a “meta-
static deposit smaller than 2 mm in diameter distinct from the
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primary lesion”.12–14 This definition has been adopted by the
Union International Contra la Cancrum (UICC)15 as well as
the American Joint Commission on Cancer (AJCC).16 Despite
various alternative definitions, isolated tumour cells (ITCs)
should be distinguished from micrometastasis, as the latter
occurs when there is contact of metastatic cells with vessel or
lymph sinus wall, extravasation, extravascular stromal reac-
tion and tumour cell proliferation.15,17 However, the tumour
node metastasis (TNM) classification of the UICC provides no
information on how to classify ITCs at multiple locations or
multiple locations of micrometastases.17 Due to the recent
introduction of the SLN procedure, the AJCC Breast Commit-
tee proposed a subclassification of micrometastasis.18 It is
widely accepted that adjuvant therapy should not be recom-
mended to patients presenting with ITCs until the prognostic
value has been validated.18–21
Detection methods of micrometastasis
Lymph nodes considered negative by standard sectioning and
staining with haematoxylin and eosin (H&E) can be shown in
some cases to contain micrometastasis by advanced detection
modalities. The most common method of detecting micro-
metastasis is pathological examination using a combination
of H&E and immunohistochemical (IHC) staining of multi-
sectioned specimens. The incidence of SLN micrometastasis
detected by this method is approximately 20% in specimens
that were thought to be negative following standard patho-
logical examination.22–27 However, no standard method has
been established concerning how to slice the specimen and
how many slides should be examined.
On the other hand, a more sensitive method utilizing the
reverse transcriptase-polymerase chain reaction (RT-PCR) has
also been applied to the detection of micrometastasis. Using
RT-PCR, an even larger proportion (53–87%) of negative SLN
can be shown to express tumour mRNA.28 However, unlike
melanoma, for which the tyrosinase marker has clearly been
identified as specific and reliable for the detection of micro-
metastasis, there is as yet no accurately defined RT-PCR marker
or set of markers for breast cancer.29 Furthermore, this method
is too sensitive to be clinically significant because it may detect
ITCs, which are not defined as metastasis according to the
sixth edition of the AJCC and UICC cancer staging manuals
for breast cancer.17 It seems unlikely that this group of cells
would escape immune surveillance and acquire the traits nec-
essary to become a macrometastasis. Thus, the American Col-
lege of Surgeons Oncology Group Z0010 trial is currently
evaluating the prognostic value of micrometastasis detected
by RT-PCR assay; it is expected to report within the next 5–
10 years.
Since the skeletal system is the most frequent site of
macrometastasis in breast cancer patients, hunting for micro-
metastasis in bone marrow is more likely to be successful.
Various immunocytochemical methods and molecular assays
have been developed to detect and characterize micrometa-
stasis in bone marrow.
SLNB for staging of local node status
SLNB is now regarded as the standard of care for staging
clinically node-negative breast cancers and melanomas,30,31
and is an investigational technique that is increasingly applied
to other solid tumours.32
It has been suggested that tumour involvement of the
SLN is the most significant prognostic factor for survival
of patients with locoregional melanoma.33 Apart from the
decreasing morbidity, therapeutic benefit has also been pre-
liminarily validated by the National Institutes of Health-
sponsored Multicenter Sentinel Lymphadenectomy Trial
and the multicentre Sunbelt Melanoma Trial.34,35 Further
data will be available soon from a randomized comparison
of wide excision versus lymphatic mapping with SLNB in
the management of clinically node-negative patients with
high-risk primary melanoma.34
The role of axillary lymph node dissection as a staging
procedure in clinically node-negative breast cancer patients is
under re-evaluation. Many studies have been conducted to
determine the accuracy of SLNB for predicting axillary lymph
node status. SLNB using radioguided surgery and/or vital
blue dye has identification rates ranging from 82% to 95%, and
100% accuracy of predicting axillary status.5–9
Clinical significance of micrometastasis in SLN
Although the clinical significance of lymph node microme-
tastasis remains controversial, most of the larger trials strong-
ly suggest that the presence of micrometastasis might have
a positive impact on disease-free and overall survival. The
International (Ludwig) Breast Cancer Study Group detected
axillary lymph node micrometastasis in 921 breast cancer
patients and recorded that after a median follow-up of 5 years,
patients with micrometastasis had a poorer disease-free (p =
0.003) and overall (p = 0.002) survival than their negative
counterparts on serial sectioning.36 They also reported that
ASIAN JOURNAL OF SURGERY  VOL 27 • NO 4 • OCTOBER 2004 281
070/2001
■ ALTERNATIVE TO AXILLARY NODE DISSECTION ■
the presence of occult micrometastasis remained statistically
significant after adjusting for other prognostic factors. Cote
et al showed quite similar results in postmenopausal but
not in premenopausal patients.37 They interpreted that IHC
remained a reliable and prognostically valuable method for
detecting nodal micrometastasis after a median follow-up
of 12 years among 736 patients. Using AE1/3 antibody to
detect axillary lymph node micrometastasis in 148 consecu-
tive “node-negative” patients, Yoshihisa et al found that the
7-year disease-free (p = 0.0009) and overall (p = 0.0001) survi-
val rates were significantly better in patients without micro-
metastasis than in patients with micrometastasis.38 Their
findings suggest that the presence of micrometastasis is an
independent and significant predictor of clinical outcome.
On the other hand, several studies provide data on patients
who had SLNB alone. In Giuliano et al’s study,39 there was no
local or axillary recurrence at a median follow-up of 39 months
in 67 SLN-negative patients. Similarly, Schrenk et al reported
no axillary recurrence at a median follow-up of 22 months in
83 patients with negative SLN.40 This result has also been
confirmed by Japanese experience.41 Although these studies
using SLNB alone did not show a detrimental impact on the
axillary failure rate in node-negative breast cancer patients, it
must be of concern that the follow-up was short and that bias
exists because of the adjuvant therapy. Moreover, since there is
a known false-negative rate for SLNB, performing the proce-
dure alone might fail to remove the disease thoroughly from
the axilla in some patients.42 In this context, SLNB should be
considered an immature technique until further work demon-
strates the clinical significance of micrometastasis in SLN.
Individual malignant cells left from the primary tumour
do not necessarily have the ability to survive and grow in a
distant organ. It has been supposed that the presence of a large
colony of metastatic cells in an SLN may be of prognostic
importance, whereas small groups of cells may not.21
Impact of bone marrow micrometastasis
on survival
Numerous studies have also been conducted to establish bone
marrow micrometastasis as a prognostic factor for survi-
val, but the results are controversial. Using an antiepithelial
polyclonal antibody to detect micrometastasis in 350 patients
with breast cancer, Mansi et al demonstrated that marrow
micrometastasis was a prognostic factor in univariate analysis,
but not an independent prognostic factor for either disease-
free or overall survival on multivariate analysis after a median
of 6 and 12.5 years’ follow-up.43,44 They postulated that some
of the micrometastatic cells might be non-viable, as Carter
et al and Page and Carter have noted for the SLN.45,46 Braun et
al used a pan-cytokeratin antibody to detect bone marrow
micrometastasis in 552 women, with 4 years of follow-up.47
The presence of micrometastasis was an independent prog-
nostic factor through multivariate analysis as well as an inde-
pendent indicator of death after adjustment for systemic
adjuvant chemotherapy. Gebauer et al found no difference in
survival in patients who received no adjuvant therapy, so
concluded that adjuvant intervention was most problema-
tic.48 They also issued a caution against over-staging patients:
“the detection of epithelial cells alone is not a sufficient defi-
nition of growing metastatic disease that might lead to clini-
cal consequence.”
Correlation between bone marrow and
lymph node micrometastasis
Although circulating tumour cells and bone marrow micro-
metastasis are always examined simultaneously, very few
studies focus on the correlation between micrometastatic cell
spread to bone marrow and to lymph nodes. As shown in an
animal model in the 1970s,49 the presence of lymph node
metastasis does not necessarily correlate with the presence
of micrometastasis in bone marrow. In the first study to di-
rectly compare the presence of lymph node micrometasta-
sis with that of bone marrow micrometastasis in presumed
node-negative patients, Braun et al found a prevalence of
9% and 29%, respectively.50 The unbiased effects of micro-
metastasis prognosis were studied because the study popu-
lation had received neither cytotoxic nor hormonal treat-
ment. Co-incidence of micrometastasis in bone marrow
and lymph nodes was detected in only two patients. Further-
more, reduced distant disease-free (p = 0.039) and overall
(p = 0.014) survival were only associated with a positive bone
marrow finding but not with lymph node micrometa-
stasis. This lack of correlation might be explained by the
presence of two independent metastatic pathways in breast
cancer, lymphogenic and haematogenic spread, determined
by different sets of genes.51
Summary
The application of SLNB and detection of micrometastasis
results in much confusion among surgical oncologists. Deter-
mining which kind of micrometastasis may provide more
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information of clinical significance for “node-negative”
breast cancer patients is complicated. Micrometastasis in the
SLN warrants further investigation, as SLNB is likely to
evolve into a standard procedure for breast cancer manage-
ment. The question of whether complete axillary dissection
can be replaced by either SLNB or detection of bone marrow
micrometastasis will be answered by ongoing randomized
clinical trials.
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